TY - JOUR
T1 - A diagnostic host-specific transcriptome response for Mycoplasma pneumoniae pneumonia to guide pediatric patient treatment
AU - Viz-Lasheras, Sandra
AU - Gómez-Carballa, Alberto
AU - Bello, Xabier
AU - Rivero-Calle, Irene
AU - Dacosta, Ana Isabel
AU - Kaforou, Myrsini
AU - Habgood-Coote, Dominic
AU - Cunnington, Aubrey J.
AU - Emonts, Marieke
AU - Herberg, Jethro A.
AU - Wright, Victoria J.
AU - Carrol, Enitan D.
AU - Paulus, Stephane C.
AU - Zenz, Werner
AU - Kohlfürst, Daniela S.
AU - Schweintzger, Nina
AU - Van der Flier, Michiel
AU - de Groot, Ronald
AU - Schlapbach, Luregn J.
AU - Agyeman, Philipp
AU - Pollard, Andrew J.
AU - Fink, Colin
AU - Kuijpers, Taco T.
AU - Anderson, Suzanne
AU - Von Both, Ulrich
AU - Pokorn, Marko
AU - Zavadska, Dace
AU - Tsolia, María
AU - Moll, Henriëtte A.
AU - Vermont, Clementien
AU - Levin, Michael
AU - Martinón-Torres, Federico
AU - Salas, Antonio
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/1/15
Y1 - 2025/1/15
N2 - Mycoplasma pneumoniae causes atypical pneumonia in children and young adults. Its lack of a cell wall makes it resistant to beta-lactams, which are the first-line treatment for typical pneumonia. Current diagnostic tests are time-consuming and have low specificity, leading clinicians to administer empirical antibiotics. Using a LASSO regression simulation approach and blood microarray data from 107 children with pneumonia (including 30 M. pneumoniae) we identify eight different transcriptomic signatures, ranging from 3-10 transcripts, that differentiate mycoplasma pneumonia from other bacterial/viral pneumonias with high accuracy (AUC: 0.84-0.95). Additionally, we demonstrate that existing signatures for broadly distinguishing viral/bacterial infections and viral/bacterial pneumonias are ineffective in distinguishing M. pneumoniae from viral pneumonia. The new signatures are successfully validated in an independent RNAseq cohort of children with pneumonia, demonstrating their robustness. The high sensibility of these signatures presents a valuable opportunity to guide the treatment and management of M. pneumoniae pneumonia patients.
AB - Mycoplasma pneumoniae causes atypical pneumonia in children and young adults. Its lack of a cell wall makes it resistant to beta-lactams, which are the first-line treatment for typical pneumonia. Current diagnostic tests are time-consuming and have low specificity, leading clinicians to administer empirical antibiotics. Using a LASSO regression simulation approach and blood microarray data from 107 children with pneumonia (including 30 M. pneumoniae) we identify eight different transcriptomic signatures, ranging from 3-10 transcripts, that differentiate mycoplasma pneumonia from other bacterial/viral pneumonias with high accuracy (AUC: 0.84-0.95). Additionally, we demonstrate that existing signatures for broadly distinguishing viral/bacterial infections and viral/bacterial pneumonias are ineffective in distinguishing M. pneumoniae from viral pneumonia. The new signatures are successfully validated in an independent RNAseq cohort of children with pneumonia, demonstrating their robustness. The high sensibility of these signatures presents a valuable opportunity to guide the treatment and management of M. pneumoniae pneumonia patients.
UR - http://www.scopus.com/inward/record.url?scp=85215757225&partnerID=8YFLogxK
U2 - 10.1038/s41467-025-55932-9
DO - 10.1038/s41467-025-55932-9
M3 - Article
C2 - 39809748
AN - SCOPUS:85215757225
SN - 2041-1723
VL - 16
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 673
ER -